Filing Details
Theriva Biologics, Inc. (AMEX:TOVX) filed a Form 8-K with the Securities and Exchange Commission on August 11, 2026, disclosing a material event.
8k filedAMEX:TOVX
Theriva Biologics, Inc. (TOVX) Reports Material Event to SEC
Theriva Biologics, Inc. (AMEX:TOVX) filed a Form 8-K with the Securities and Exchange Commission on August 11, 2026, disclosing a material event.
At publication ·
What changed
Theriva Biologics, Inc. (AMEX:TOVX) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Theriva Biologics, Inc. (TOVX) filed a Form 8-K with the SEC on August 11, 2026, disclosing a material event that shareholders should be aware of, though the specific nature of the event is not detailed in this filing notice.
- The company's stock trades at $0.23 per share with a market capitalization of $7.8 million as of the filing date.
- Material events reported on Form 8-K can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance, and the stock moved following this disclosure.
Market Context
Theriva Biologics, Inc.'s stock currently trades at $0.23 with a market capitalization of $7.8M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Theriva Biologics, Inc.'s stock.
All SEC filings for Theriva Biologics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View TOVX Stock Page
Frequently Asked Questions
Where can I read TOVX's SEC filings?
Browse all filings on our TOVX SEC filings page.
What types of SEC filings does Theriva Biologics, Inc. file?
Public companies like Theriva Biologics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.